$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

OMT-111 for Terminal Stage Solid Tumors

2020-10

2022-06-30

2022-10

78

Study Overview

OMT-111 for Terminal Stage Solid Tumors

Patients with terminal stage of metastatic non-small cell lung cancer, metastatic triple negative breast cancer, or advanced or metastatic pancreatic adenocarcinoma resisting to standard therapies.

This is a multi-site, single arm, Phase II study designed to explore the efficacy of OMT-111 in patients with terminal stage solid tumors resistant to standard therapies. Subjects who voluntarily provide written consent to participate in this study undergo screening tests within 4 weeks prior to the first dose of investigational product. Those who meet the inclusion/exclusion criteria are enrolled in the study. 1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval (20 days of treatment and 8 days of treatment-free interval per cycle in total). This study is planned to enroll approximately 76 subjects including 42 subjects with lung cancer, 22 subjects with breast cancer, and 12 subjects with pancreatic cancer. Treatment will be provided for 12 cycles (48 weeks). During the study, tests and procedures to evaluate the efficacy and safety will be carried out according to the planned schedule.

  • Breast Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • DRUG: OMT-111
  • Metimedi-202

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2020-08-12  

N/A  

2020-09-08  

2020-08-18  

N/A  

2020-09-09  

2020-08-20  

N/A  

2020-09  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Open label single arm

1 cycle consists of 4 weeks (28 days). Each week consists of 5 days of treatment and 2 days of treatment-free interval

DRUG: OMT-111

  • Pre-filled Syringe
Primary Outcome MeasuresMeasure DescriptionTime Frame
Disease Control Rate (DCR)Every two cycles (8 weeks)From the start of treatment to 48 weeks.
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Objective Response Rate (ORR)Every two cycles (8 weeks)From the start of treatment to 48 weeks.
Duration of Response (DoR)Every two cycles (8 weeks)From the start of treatment to 48 weeks.
Progression-Free Survival (PFS)Every two cycles (8 weeks)From the start of treatment to 48 weeks.
18F-FDG- PET/CT (SUVmean and SUVmax)Every two cycles (8 weeks)From the start of treatment to 48 weeks.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: DongChul Kim

Phone Number: 84-93-510-7310

Email: dongchool.kim@bigleapresearch.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Breast Cancer

    • 1. Female at least 18 years old or older at the time of informed consent 2. Histologically or cytologically confirmed triple negative ductal adenocarcinoma of breast 3. Patients who have visceral metastatic lesions not amenable by resection or radiotherapy (e.g., multiple visceral lesions) 4. ECOG PS (Eastern Cooperative Oncology Group Performance Status): 0-2 5. Patients with a life expectancy ≥ 12 weeks as judged by the investigator 6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Pancreatic Cancer

    • 1. Male or female at least 18 years old or older at the time of informed consent 2. Histologically or cytologically confirmed adenocarcinoma of pancreas 3. Patients who have advanced or metastatic lesions not amenable by resection or radiotherapy 4. ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤ 2 5. Patients with a life expectancy ≥ 12 weeks as judged by the investigator 6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  • Lung Cancer

    • 1. Male or female at least 18 years old or older at the time of informed consent 2. Histologically or cytologically confirmed carcinoma of the lung (small cell lung cancer not included) 3. Patients who have unresectable metastatic lesion 4. ECOG PS (Eastern Cooperative Oncology Group Performance status) ≤ 2 5. Patients with a life expectancy ≥ 12 weeks as judged by the investigator 6. At least one measurable lesion or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
    Exclusion Criteria:

  • Breast Cancer

    • 1. History of malignancy other than metastatic triple negative breast cancer within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible) 2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days without steroids) are eligible) 3. Primary cancer-related complications potentially requiring urgent surgery as judged by the investigator 4. Grade ≥ 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0 5. History of one or more of the following cardiovascular diseases

  • Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)
  • Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)
  • Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator
  • QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1) 6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1) 7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis 8. Previous treatment with the investigational product 9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product 10. Unable to come to the site hospital on a daily basis for investigational product administration 11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment.
  • Pancreatic Cancer

    • 1. History of malignancy other than advanced or metastatic pancreatic adenocarcinoma within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible) 2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days without steroids) are eligible) 3. Primary cancer-related complication potentially requiring urgent surgery as judged by the investigator 4. Grade ≥ 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0 5. History of one or more of the following cardiovascular diseases

  • Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)
  • Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)
  • Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator
  • QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1) 6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1) 7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis 8. Previous treatment with the investigational product 9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product 10. Unable to come to the site hospital on a daily basis for investigational product administration 11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment
  • Lung Cancer

    • 1. History of malignancy other than metastatic non-small cell lung cancer within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible) 2. Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days) are eligible) 3. Primary cancer-related complication potentially requiring urgent surgery as judged by the investigator 4. Grade ≥ 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0 5. History of one or more of the following cardiovascular diseases

  • Cerebrovascular disease, unstable angina, or myocardial infarction within 6 months prior to the screening visit (Visit 1)
  • Congestive heart failure corresponding to New York Heart Association (NYHA) Class III or above (see Appendix 1. NYHA Classification)
  • Serious cardiac arrhythmia not controlled with medication or clinically significant cardiovascular abnormality as judged by the investigator
  • QTc > 480 msec (Fredericia's formula) during 12-lead ECG at screening visit (Visit 1) 6. Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit (Visit 1) 7. Renal impairment or chronic renal failure patient requiring hemo- or peritoneal dialysis 8. Previous treatment with the investigational product 9. Treatment with other investigational product within 30 days prior to the first dose of the investigational product 10. Unable to come to the site hospital on a daily basis for investigational product administration 11. Patients who are otherwise considered to be ineligible for this study based on investigator's judgment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • STUDY_DIRECTOR: Soobong Park, MetiMedi Pharmaceuticals

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    Treat yourself

    Let Us Take Care Of You

    BOOK AN APPOINTMENT ⟶
    footer logo

    About

    Events

    Fundraising

    Contact Us

    Facebook-f Instagram

    NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

    The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

    Copyright © 2025 – National Pancreatic Cancer Foundation | All Rights Reserved

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate